On December 26, an innovative drug research and development company that focuses on stem cell and gene therapy technologies, targets blinding eye diseases, and is committed to advancing from "no available treatment" to "precise cure."Theia TherapeuticsAnnounced the completion of a multi-million RMB Pre-A1 round of financing in recent days.This round of financing was jointly invested by Shenzhen Future XinZhi Technology Investment Partnership (Limited Partnership) (hereinafter referred to as "Future XinZhi") and Harmony Beyond SME Development Fund (Yixing) Partnership (Limited Partnership) (hereinafter referred to as "Harmony Beyond"). The angel round investor, LSV CAPITAL (hereinafter referred to as "LSV"), has shown strong confidence and continued additional investment, reflecting the capital market's high recognition of the company’s development path and potential.ExpectedReadReading Time: 5 Minutes
This round of fundraising will be used to support the pipeline development and clinical advancement of the "iPSC-derived Retinal Pigment Epithelial Cells for the Treatment of Macular Degeneration" project., further solidify and expand the core technology platform, build deeper competitive barriers, attract top global scientific research and industry talents to join, and strengthen the R&D, clinical, and management teams, laying a solid foundation for future product launches and international market expansion. The company will continue to enrich its R&D pipeline, broaden therapeutic areas and target populations, and accelerate the value realization of Theia Therapeutics. The success of this financing round represents high recognition and strong confidence from the capital market in Theia Therapeutics' technical strength, R&D pipeline value, and future development potential in the field of ophthalmic cell and gene therapy, marking the company’s entry into a new accelerated phase of development.Cultivating the Blue Ocean: Focusing on Unmet Clinical Needs
Since its inception, Theia Therapeutics has focused on blinding eye diseases, a field with significant unmet clinical needs. The company understands that for many patients suffering from vision loss or even blindness, traditional therapies have limited efficacy, and revolutionary treatments are urgently needed. Under the inspiring vision of "Repairing sight, enabling an enduring dialogue between the soul and light," Theia Therapeutics is committed to the mission of "Providing accessible curative solutions for patients with blinding eye diseases worldwide through breakthrough cell and gene therapies." Focusing on blinding eye diseases, the company aims to drive a leap from "no available treatment" to "precise cure."Currently, the company's pipeline covers major blinding diseases such as age-related macular degeneration (AMD), high myopia, juvenile macular degeneration (Stargardt disease), and corneal blindness, promoting the seamless integration of research and medical needs. It provides breakthrough treatment solutions for patients with eye diseases globally, significantly improving their quality of life.The person in charge of Shenzhen Future Intelligence Technology Investment Partnership (Limited Partnership) said"As an important investment in the cell and gene therapy field, Theia Therapeutics embodies our firm belief in the long-term value of the ophthalmology sector. There is a significant unmet clinical need in ophthalmic diseases, offering vast market potential. With its innovative therapies, platform technologies, and solid scientific research capabilities, Theia Therapeutics has established a clear first-mover advantage. The team not only demonstrates deep R&D expertise but also exhibits exceptional execution by rapidly advancing core pipelines to a leading position in China. We believe that Theia Therapeutics' innovative platform has the potential to bring breakthrough advancements to ophthalmic treatments. Moving forward, LSV CAPITAL will continue to uphold the philosophy of 'investment companionship and value co-creation,' fully supporting the company in advancing clinical research and global expansion. Together, we aim to accelerate the implementation of cutting-edge therapies, making innovative technologies accessible to patients worldwide."Partner of LSV CAPITAL stated"As an angel round investor, we have accompanied Theia Therapeutics all the way, experiencing its entire journey from scientific discovery, technological conception through concept validation to the solid advancement of its pipeline. Theia Therapeutics is an outstanding project graduated from the shared space of LSV CAPITAL, with a globally disruptive innovative R&D pipeline that addresses significant unmet needs in ophthalmology. The team not only possesses deep industry insights and scientific research capabilities but also demonstrates persistent pragmatism and highly efficient execution. Our continued additional investment is based on our profound recognition of Theia Therapeutics' strategic layout and firm confidence in its long-term development potential. We look forward to the company continuously leading innovation and moving towards more important milestones in its new phase of development!"Mr. Fang Riguo, Co-founder and CEO of Theia Therapeutics, stated："We sincerely thank all the investors in this round for their strong support and trust! The completion of this round of financing is an affirmation of the efforts made by the team at Theia Therapeutics in the past, and more importantly, a powerful engine for our accelerated development in the future. We always keep patients in mind, using science as the oar and innovation as the sail. This funding will enable us to advance highly promising therapeutic products into clinical trials and bring them to market more quickly. We will continue to focus on the field of ophthalmic cell and gene therapy, deepen technological innovation, accelerate pipeline development, and aspire to become a leader in ophthalmic cell and gene therapy in China and even globally, bringing hope of restoring vision to countless patients suffering from eye diseases!"With the support of capital, Theia Therapeutics has been injected with strong momentum. Standing at a new starting point, Theia Therapeutics will accelerate the development of innovative therapies with greater speed and higher quality. We look forward to joining hands with partners from the industry, medical, and investment communities to illuminate the future of human vision health together!
